Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

(2018) Natalie J. Neubert et al.   Science Translational Medicine

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves

(2018) David P. Enot et al.   OncoImmunology

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

(2018) Laure Hirsch et al.   BRITISH JOURNAL OF CANCER

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells

(2016) Ilaria Marigo et al.   CANCER CELL

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming

(2016) M. E. Rodriguez-Ruiz et al.   CANCER RESEARCH

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

(2016) Xiaohong Wang et al.   CANCER RESEARCH

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy

(2016) Albert W. Girotti et al.   CURRENT MEDICINAL CHEMISTRY

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Type I IFN Inhibits Alternative Macrophage Activation duringMycobacterium tuberculosisInfection and Leads to Enhanced Protection in the Absence of IFN-γ Signaling

(2016) Lúcia Moreira-Teixeira et al.   JOURNAL OF IMMUNOLOGY

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

(2016) Nicolas Jacquelot et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy

(2016) Nadeem Riaz et al.   NATURE GENETICS

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

(2015) Shin Foong Ngiow et al.   CANCER RESEARCH

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

New perspectives on type I IFNs in cancer

(2015) Thomas F. Gajewski et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Cancer and the Immune System: Basic Concepts and Targets for Intervention

(2015) Drew Pardoll   SEMINARS IN ONCOLOGY

The dual role of iNOS in cancer

(2015) Federica Vannini et al.   Redox Biology

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons

(2014) Olivier Dussurget et al.   Frontiers in Cellular and Infection Microbiology

NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data

(2012) Daryl Waggott et al.   BIOINFORMATICS

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Targeted gene knockout by direct delivery of zinc-finger nuclease proteins

(2012) Thomas Gaj et al.   NATURE METHODS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis

(2011) Hannelien Verbeke et al.   CANCER LETTERS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonconventional Initiation Complex Assembly by STAT and NF-κB Transcription Factors Regulates Nitric Oxide Synthase Expression

(2010) Matthias Farlik et al.   IMMUNITY

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

(2008) Paulo C. Rodríguez et al.   IMMUNOLOGICAL REVIEWS